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The protein levels of -catenin are tightly regulated by the ubiq-
uitinproteasome system. We provide evidence that two distinct
ubiquitin-dependent degradation pathways for -catenin are ac-
tive in the same Burkitt’s lymphoma cells: Along with the classical
glycogen-synthase kinase 3-dependent destruction machinery,
degradation of -catenin through seven in absentia homolog 1
(Siah-1) ubiquitin ligase is functional in these cells. We show that
inhibition of endogenous Siah-1 stabilizes and activates -catenin
in B cells. The principal Epstein–Barr virus oncoprotein, latent
membrane protein 1, is involved in -catenin up-regulation, and
expression of latent membrane protein 1 in B lymphoma cells is
associated with decreased Siah-1 RNA and protein levels. Thus, we
demonstrate the significance of the endogenous Siah-1-dependent
ubiquitinproteasome pathway for -catenin degradation in ma-
lignant human cells and its regulation by a viral oncogene.
B lymphoma  ubiquitinproteasomal degradation  Epstein–Barr virus 
latent membrane protein 1
The protein -catenin has critical functions in several normal andmalignant intracellular processes. In cell-adhesion signaling,
-catenin binds the cytoplasmic domain of cadherin adhesion
receptors along with -catenin to transmit signals from cadherins to
the underlying actin cytoskeleton (1). The cytoskeletal network of
adherent cells is considered essential for normal tissue architecture
and morphogenesis. When part of the transcriptional machinery in
the nucleus, -catenin can bind to TcfLef factors and serve as a
transcriptional coordinator for activation of target genes (2). The
balance of -catenin between these two functional complexes might
be explained by distinct molecular forms of -catenin that exist in
cells (3), but the mechanism of this regulation still remains to be
explored. In the meantime, it is well established that, in general, the
protein levels of -catenin are regulated by the ubiquitin-
proteasome system (UPS) (2, 4).
Understanding of the mechanism of -catenin regulation
through the UPS came primarily from the study of canonical Wnt
signaling in which -catenin stabilization plays a central role (4).
According to the most accepted model, -catenin is efficiently
targeted for ubiquitination and degradation by a multiprotein
complex, including the serinethreonine kinase, glycogen-synthase
kinase 3 (GSK3), the scaffold proteins, Axinconductin, and the
adenomatosis polyposis coli tumor-suppressor protein (2, 4). Mu-
tations in the components, such as Axin or adenomatosis polyposis
coli, can be sufficient for functional activity of this destruction
complex (2). Initial phosphorylation of -catenin by casein kinase
1 precedes its further phosphorylation by GSK3 on the NH2
terminus of -catenin (5). Phosphorylation of -catenin by GSK3
is essential for the ubiquitination of -catenin mediated by the
SCF-TrCP ubiquitin ligase, in combination with the Skp1 and
Cullin1 ubiquitin-conjugating complex (6). Initiation of classic Wnt
signaling leads to inhibition of GSK3-dependent phosphorylation
and degradation of -catenin and, as a result, activation of the
-cateninTcf transcriptional pathway (4). Because of the fact that
inhibition of GSK3 is a key point in rescue of -catenin from
phosphorylation-dependent destruction, other cell signaling path-
ways affecting GSK3 kinase activity have been implicated in
-catenin signaling (7).
Also, a different pathway of -catenin ubiquitination and pro-
teasomal degradation has been uncovered. In this case, a distinct
ubiquitin–ligase complex, Siah-1-SIP-Skp1-Ebi, promotes degrada-
tion of -catenin through a mechanism independent of GSK3-
mediated phosphorylation (8, 9).
Siah (seven in absentia homolog) proteins are members of an
evolutionarily highly conserved family of E3 ubiquitin ligases. They
bind ubiquitin-conjugating enzymes via an N-terminal RING do-
main and target other proteins for ubiquitination and proteasomal
degradation (10). Besides -catenin, several important targets of
the Siah-dependent ubiquitinproteasome pathway have been iden-
tified (11, 12). Siah proteins are implicated in a variety of cellular
processes, such as apoptosis and tumor suppression. Some studies
have also suggested that human Siah-1 acts as a downstream
effector of p53 (8, 9). However, the biological significance of
Siah-dependent -catenin ubiquitination and its regulation in nor-
mal and cancer cells is largely unknown.
The ability of Epstein–Barr virus (EBV) to transform normal
resting B cells into indefinitely proliferating lymphoblastoid cell
lines is a successful viral strategy for survival and the basis of several
human malignancies. EBV immortalizes B lymphocytes through
viral proteins that modify cellular gene expression at the level of
transcription directly or indirectly by dysregulating cell signaling
pathways. In type III EBV latency, exemplified by EBV lympho-
proliferative disease in immunocompromised hosts, all nine viral
latency products are expressed (13). Among them, latent mem-
brane protein 1 (LMP1) is of particular interest as a primary EBV
oncogene because it transforms rodent fibroblasts in vitro and
induces lymphomas in transgenic mice (13). In addition, it can
dysregulate cell signaling pathways and induce a variety of cellular
genes that enhance cell survival and adhesive, invasive, and angio-
genic potential (13, 14).
Human tumor viruses, including EBV, can activate the -catenin
signaling by different mechanisms (15–17). In this study, we show
that two distinct pathways of -catenin destruction through the
ubiquitin-proteasome system coexist in the same lymphoid cells,
and that the EBV oncoprotein LMP1 up-regulates -catenin by
increasing its stability through inhibition of Siah-1-mediated ubiq-
uitination.
Materials and Methods
Plasmids. Wild-type pcLMP1 has been described in ref. 18. Tcf
reporter plasmids, TOPFlash (optimal Tcf-binding site) and FOP-
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Flash (mutated Tcf-binding site) were obtained from Upstate
Biotechnology. pHA-ubiquitin encodes a hemagglutinin (HA)-
tagged ubiquitin was a gift from Y. Xiong (University of North
Carolina). Both wild-type and mutant forms (S37A) of -catenin-
expressing plasmids were kindly provided by S.-G Hwang,
(Kwangju Institute of Science and Technology, Gwangju, Korea).
pSiah1–75 plasmid, which expresses a Siah-1 dominant-negative
mutant (Siah-1DN), has been described in ref. 9. The small
interfering RNA (siRNA) duplexes were synthesized and purified
by Qiagen (Cambridge, MA). Siah-1L target sequence was as
follows: siSiah-1L, 5-AACTCCTGCCTCCTTATGTATTT-3.
The nonsilencing siRNA (control siRNA) sequence was as follows:
siCTR, 5-AAGAGCCGTCAGACTGCTACA-3.
Cell Culture and Transient Transfection. DG75 is an EBV-negative
Burkitt’s lymphoma (BL) cell line (19). Sav I and Sav III are
genetically identical BL cell lines that differ in their EBV latency
status (20). BL41-P3HR1 and BL41-B95-8 are cell lines prepared
by infection of EBV-negative BL41 cells with the two different EBV
strains, P3HR1 and B95-8 (21). Lymphoblastoid cell lines (LCL-23,
-45, -67, and -89), generated by infecting B cells from anonymous
healthy donors with B95-8 EBV strain, were provided by the Tissue
Culture Facility of the Lineberger Cancer Center. All cells were
maintained in RPMI 1640 medium plus 10% FBS. Cells were
transfected by an electroporation method with the use of the
Bio-Rad Gene Pulser at 210 V and 975 F at the indicated
concentrations of the LMP1-expressing plasmid. Vector DNA was
added to equalize the total amount of DNA (10 g) used in all
transfections. After electroporation, cells were resuspended in 10
ml of complete medium and incubated for 48 h before harvesting.
Western Blot Analysis. Cells were lysed in lysis buffer [50 mM Hepes,
pH 7.4150 mM NaCl10% glycerol1 mM EDTA1 mM sodium
orthovanadate100 mM NaF1% Triton X-100protease inhibitor
mixture (Roche Diagnostics)]. Protein concentration was deter-
mined by the Bradford assay (Bio-Rad). Total cell proteins were
resolved on SDSPAGE, transferred to nitrocellulose membrane
(Osmonics), blocked in 5% milkTris-buffered saline solution, and
incubated at room temperature for 2 h with -catenin (BD Trans-
duction Laboratories), LMP1 (DAKO), and -tubulin (Sigma),
Siah-1 (Transgenic) and Myc-tag (Cell Signaling Technology)
antibodies. After washing with TBST for 10 min three times, the
membrane was incubated with appropriate secondary antibody at
room temperature for 1 h, washed three times with TBST as before,
treated with SuperSignal (Pierce) detection reagents, and exposed
to Kodak XAR-5 film.
Luciferase Reporter Assay. For dual-luciferase reporter assay, DG75
cells were transiently transfected with 3 g of Tcf reporter plasmids,
TOPFlash or FOPFlash, and the indicated amounts of the effector
plasmid as described above. To control for transfection efficiency,
a control reporter, pRL-TK (0.1 g), which contains a herpes
simplex virus thymidine kinase promoter driving a Renilla luciferase
gene, was cotransfected. After 48 h, cells were lysed in passive lysis
buffer, and luciferase activities were monitored in cell lysate with
the use of Dual-Luciferase assay reagents (Promega) as described
by the manufacturer. All reporter assay results presented are from
two independent experiments prepared in triplicate.
Immunoprecipitation. DG75 cells were cotransfected with HA-
tagged ubiquitin-encoding plasmid and increasing amounts of
LMP1-expressing plasmid as described. Whole-cell lysates were
precleared with AG PLUS-Agarose beads for 30 min at 4°C and
incubated with anti-HA tag antibody (Santa Cruz Biotechnology)
for an additional hour and then with beads overnight at 4°C. After
intensive washing and centrifugation, immune complexes were
separated by SDSPAGE and probed with -catenin antibody by
Western blotting.
RT-PCR. Total cellular RNA was extracted from cells with the use
of TRIzol (GIBCO). DNase I-digested RNA (3 g) was reverse-
transcribed with the corresponding antisense primer. One-
quarter of the reverse-transcribed RNA was amplified with Taq
polymerase (95°C for 5 min; 30 cycles at 95°C for 1 min, 56°C for
1 min, 72°C for 30 sec, and 72°C for 5 min) by using sense primers
5-GAC TGG CAC AAC TGC ATC CA-3, 5-CTT CGA AAG
AGA CCT TCT CT-3, and 5-ATG GGG AAG GTG AAG
GTC GG-3 and antisense primers 5-AGC CAA GTT GCG
AAT GGA TC-3, 5-ACA ATG CCT GTC CGT GCA AA-3,
and 5-TGG AGG GAT CTC GCT TG-3 for Siah-1, LMP1, and
GAPDH, respectively.
The real-time RT-PCR reactions were performed in a volume of
20 l containing oligonucleotide primers (5 M of each), MgCl2 (5
mM), one-tenth of the cDNA (2 l), and DNA Master SYBR green
(Roche Molecular Biochemicals) containing Taq DNA polymer-
ase, reaction buffer, dNTP, and the double-stranded DNA-specific
fluorescent dye SYBR Green I. Amplification was carried out in
two steps: preincubation at 95°C for 10 min and 45 cycles with
denaturation at 95°C for 15 sec, annealing at 56°C for 7 sec, and
extension at 72°C for 9 sec. Acquisition of the fluorescent signal
from the samples was carried out at the end of the elongation step.
Results
First, we compared endogenous levels of LMP1 and -catenin in
several B lymphocytic lines to find whether there was any correla-
tion between LMP1 and -catenin expression. We used several
Burkitt’s lymphoma cell lines, including BL41-P3HR1 and BL41-
B95, infected by the prototype EBV B95–8 strain or the defective
P3HR1 virus, respectively. BL41-P3HR1 cells express very low
levels of LMP1, whereas BL41-B95 cells express high levels. When
these lines were compared with the parental line by Western
blotting, only BL41-B95-8 cells had a high level of -catenin (Fig.
1a, lanes 1–3). These results are consistent with the previous report
by Everly et al. (22), in which the authors observed an increase in
the level of total -catenin protein in EBV-infected Burkitt’s
lymphomas and no difference in mRNA levels. Additional evidence
came from comparison of LMP1 and -catenin levels in four
different type III latently EBV-infected lymphoblastoid cell lines
(LCLs) that expressed different levels of LMP1. A 40% decrease in
LMP1 levels correlates with 6.5-fold lower -catenin levels in LCLs
(Fig. 1a, lanes 4–7). These observations suggest that LMP1 as a
product of type III latency up-regulates -catenin in B cells.
To investigate whether LMP1 is sufficient for the up-regulation
of -catenin, an LMP1-expressing plasmid was introduced into an
EBV-negative B cell line, DG75. The exogenously introduced
LMP1 increased the level of -catenin in a dose-dependent manner
(Fig. 1b), confirming the direct role of LMP1 in the accumulation
of -catenin in B cells. To determine whether the increased
-catenin is transcriptionally active, we transfected cells with re-
porter plasmids containing wild-type (TOPFlash) and mutant
(FOPFlash) binding sites for Tcf (23). Fig. 1c shows that LMP1
specifically induces Tcf reporter activity. These results indicate that
at least some of the LMP1-induced -catenin is transcriptionally
active.
The level of -catenin is normally regulated by UPS. As shown
in Fig. 2a, lane 1, the -catenin level in DG75 cells is maintained
at a low level, but in the presence of the proteasome inhibitor
MG101, it accumulates dramatically (Fig. 2a, lane 3), indicating that
-catenin in these B lymphoma cells is constitutively recycled by
proteasome machinery. LMP1 partly stabilizes -catenin (Fig. 2a,
lane 2), but in the presence of MG101, there is additional accu-
mulation of the protein (Fig. 2a, lane 4). Ubiquitination is usually
a necessary step that precedes proteasomal degradation (24). To
examine whether LMP1 affects -catenin on the level of ubiquiti-
nation, we introduced HA-tagged ubiquitin along with LMP1 into
DG75 cells and immunoprecipitated ubiquitin-complexed prod-
ucts. As shown in Fig. 2b, the amount of ubiquitin-complexed
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-catenin decreased significantly in the presence of LMP1, which
indicates that LMP1 reduces -catenin degradation at the level of
ubiquitination or upstream of it.
As part of the ligase complex, -TrCP1 recognizes -catenin as
a substrate for ubiquitination only when it is phosphorylated by
GSK3 at both Ser-33 and Ser-37 residues (25). Indeed, use of
nonphosphorylable mutants of -catenin and the pharmacological
inhibitor of GSK3, LiCl, has demonstrated activation of -catenin
through inhibition of ubiquitin-dependent degradation (26). We
therefore introduced a nonphosphorylable form of -catenin,
S37A, which has Ala instead of Ser at position 37, into DG75 cells.
The results indicate that the -catenin S37A mutant is more stable
and transcriptionally active than wild type -catenin (Fig. 3 a, lanes
1 and 3, and b, columns 1 and 2). Similar results were obtained in
the presence of LiCl; inhibition of GSK3 activity increases -cate-
nin protein levels (Fig. 3a, lanes 1 and 5) and Tcf reporter activity
(Fig. 3c, columns 1 and 2). These results are consistent with our
previous observation that the GSK3Axinadenomatosis polyp-
osis coli destruction complex of -catenin is intact and functionally
active in EBV-infected B lymphoma cells (20). Taken together,
these data lead to the conclusion that GSK3-dependent degra-
dation machinery for -catenin is active in B lymphoma cell lines.
Unexpectedly, expression of LMP1 further increased stabiliza-
tion of the nonphosphorylable form of -catenin (Fig. 3a, compare
lanes 3 and 4) and the transcriptional activity of -cateninTcf
complex (Fig. 3b, column 3). Moreover, LMP1 amplified protein
accumulation and transcriptional activation of -catenin induced by
inhibition of GSK3 with LiCl (Fig. 3 a, lane 6, and c, column 3).
These results do not rule out that LMP1 can inhibit GSK3-
dependent -catenin destruction machinery but suggest that LMP1
is also involved in inhibition of another degradation pathway for
-catenin in these cells.
In contrast to GSK3-dependent ubiquitinproteasomal degra-
dation of -catenin through SCF-TrCP ubiquitin ligase complex,
ubiquitination by Siah-1SIP-Skp1-Ebi does not requires -catenin
phosphorylation at its N terminus (8, 9). Because LMP1 appears to
inhibit degradation of -catenin at least, in part, through a mech-
anism other than GSK3-dependent ubiquitination, we next ex-
plored whether Siah-1-dependent destruction is involved in the
regulation of -catenin by LMP1. First, we examined Siah-1 and
Fig. 1. LMP1 up-regulates -catenin in B-cell lines. (a)
Correlation of -catenin and LMP1 protein levels in
EBV-positive and -negative B cell lines. Total cell lysates
were probed with -catenin and LMP1 antibodies.
Each band was quantified with the use of BIOPRORIL BIO 1D
image analysis software (Vilber Lourmat, Marne-la-
Vallée, France). (b) LMP1 expression increases -cate-
nin levels in EBV-negative B lymphoma cells. Increasing
amounts of LMP1-expressing vector (pcLMP1) were
transfected into DG75 for 48 h, and protein levels of
-catenin and LMP1 were detected with indicated an-
tibodies. (c) Increase of -cateninTcf transcriptional
activity by LMP1. pcLMP1 (1 g) was cotransfected
with either wild-type (TOPFlash) or mutant (FOPFlash)
reporter plasmids into DG75 cells. The total amount of
DNA was kept at 10 g. After 48 h of transfection,
luciferase activity was determined. The data represent
two independent experiments prepared in triplicate.
Fig. 2. LMP1 reduces ubiquitination of -catenin
in B lymphoma cells. (a) DG75 cells were either
mock-treated (lanes 1 and 2) or treated with 10 M
MG101 (lanes 3 and 4) in the presence (lanes 2 and
4) or absence (lanes 1 and 3) of LMP1 for 4 h, and
the level of -catenin was determined. (b) Increas-
ing amounts of pLMP1 (0, 1, and 3 g, respectively)
were transfected along with pHA-ubiquitin (3 g)
into DG75 cells for 48 h. The total amount of DNA
was kept at 10 g. Ubiquitin-conjugated products
were immunoprecipitated with HA antibody and
pulled down with AG PLUS-Agarose. The level of
ubiquitin-attached -catenin was detected by
Western blotting with -catenin antibody. As a
loading control, the amount of IgG in the precipi-
tates and the level of tubulin in the total lysates are
shown. Each band was quantified as described in
Fig. 1a. (b Right) The correlation between total and
ubiquitinated -catenin.








-catenin levels after introducing LMP1 into DG75 cells and found
that with increasing amounts of LMP1, the protein levels of Siah-1
decreased, which directly correlates with -catenin stabilization
(Fig. 4a, lanes 1–3). To provide biological significance for this
finding, we investigated whether Siah-1 expression correlates with
the latency status of EBV-infected B-cells. We compared Siah-1,
-catenin, and LMP1 endogenous levels in the genetically identical
BL cell lines Sav I and Sav III that differ in their EBV latency status:
type I and type III, respectively (Fig. 4a, lanes 4 and 5), and
observed a similar effect: The protein level of Siah-1 is higher in
type I latency than in type III. To examine whether the ubiquitin
ligase activity of Siah-1 is important for -catenin degradation in B
cells, we introduced a Siah-1 inactive mutant, Siah-1DN (9), into
DG75 cells. The functionally inert Siah-1 mutant significantly
increased transcriptional activity of -catenin (Fig. 4b, compare
columns 1 and 3) and protein levels (Fig. 4c, compare lanes 1 and
Fig. 3. LMP1 is involved in GSK3-independent acti-
vation of -catenin. (a) The level of -catenin in DG75
cells after transfection with either wild-type (WT) or
mutant form (S37A) of -catenin (1 g) for 48 h in the
presence or absence of LMP1 (1 g) was compared. For
lanes 5 and 6, cells were treated with 20 mM LiCl for
24 h. (b) TcfLef transcriptional activity in DG75 cells
transfected with either WT or mutant form of -cate-
nin in the presence or absence of LMP1. The data
indicate the average fold of TOPFlashFOPFlash from
two independent experiments prepared in triplicate.
(c) LMP1 (0, 1, and 3 g) was cotransfected with lucif-
erase reporter into DG75 cells in the presence or ab-
sence of 20 mM LiCl, and luciferase assay was per-
formed as described in Fig. 3b. In each experiment, the
total amount of DNA was kept at 10 g.
Fig. 4. Inhibition of Siah-1 ubiquitin ligase up-regulates -catenin in B lymphoma cells. (a) LMP1-dependent reduction of Siah-1 expression. DG75 cells were
transfected with 0, 1, and 3 g of pcLMP1 (lanes 1–3). After 48 h of transfection, the protein levels of LMP1, -catenin and Siah-1 were determined with the indicated
antibodies. Inaddition,genetically identicalBLcell lines, Sav Iand III,wereused(lanes4and5). (b) Functional inhibitionofSiah-1ubiquitin-ligase increases-cateninTcf
transcriptional activity. One microgram of Myc-tagged Siah-1 dominant-negative mutant-expressing plasmid (pSiah-1DN) was transfected into DG75 in the presence
or absence of pcLMP1 (1 g). The data indicate the average fold of TOPFlashFOPFlash from two independent experiments prepared in triplicate. (c) Functional
inhibition of Siah-1 ubiquitin-ligase increases -catenin protein stabilization. One microgram of pSiah-1DN was transfected into DG75 cells in the presence or absence
of pcLMP1 (1 g). In each experiment, the total amount of DNA was kept at 10 g. The expression of Siah-1DN was detected with an anti-c-Myc antibody. (d) Inhibition
of endogenous Siah-1 expression stabilizes -catenin. Siah-1 siRNA was transfected at the indicated concentration in the absence (lanes 1, 3, and 5) or presence (lanes
2, 4, and 6) of pcLMP1 (1 g). The final concentration of siRNA in each transfection was made up to 50 nM by supplementation with a control siRNA. Protein levels of
-catenin, Siah-1, and LMP1 were detected with indicated antibodies.
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3), indicating that Siah-1 ubiquitinating activity plays a certain role
in down-regulation of -catenin in these cells. Moreover, the
presence of LMP1 did not alter -catenin activation by Siah-1DN
(Fig. 4 b and c). In addition, we used Siah-1 siRNA to inhibit the
expression of endogenous Siah-1. Introduction of Siah-1 siRNA
into DG75 cells inhibited Siah-1 expression in a dose-dependent
manner and, as a result, the expression level of -catenin was
increased (Fig. 4d). Consistent with results of the Siah-1 dominant-
negative experiment, the stabilizing effect of LMP1 on -catenin
was abolished when Siah-1 expression was inhibited by the siRNA.
There are several possible mechanisms whereby LMP1 can
regulate Siah-1 expression. LMP1 interrupts signaling pathways on
different levels, including at the level of transcription. To investigate
whether LMP1 regulates Siah-1 transcriptionally, we performed
semiquantitative and real-time RT-PCR assays with Siah-1 mRNA
from DG75 cells in the presence and absence of LMP1. As shown
in Fig. 5 exogenous expression of LMP1 reduces endogenous levels
of Siah-1 mRNA in a dose-dependent manner. These experiments
indicate that LMP1 signaling can regulate Siah-1 gene expression.
Taken together, our results demonstrate that both GSK3- and
Siah-1-dependent pathways of -catenin ubiquitinproteasomal
degradation are active in human B lymphoma cells, and the viral
oncogene LMP1 participates in stabilization of -catenin in these
cells through inhibition of Siah-1-mediated destruction.
Discussion
The UPS is one of the most powerful mechanisms that controls
cellular processes (27). For many major participants in cell signal-
ing, including -catenin, the lifetime of the target protein depends
on coherence of all components of UPS. Dysregulation of the
mechanism at any level disrupts the functional balance in cells and
accounts for many diseases (28).
The regulation of -catenin is an example of a cell strategy in
which an expressed protein is a constitutive target for destruction
by the proteasome machinery. In most adherent cells, a certain
amount of -catenin is necessary for normal function of cell-cell
adherent junctions, and as a part of the cytoskeletal complex,
-catenin is considered to be invisible to the proteasome machinery
(1). In contrast to adherent cells, studies with B lymphoma cells that
grow in suspension reveal low levels of total -catenin (refs. 15, 20,
and 22; this work); even overexpressed wild-type -catenin is barely
detectable (Fig. 3a). At the same time, the amount of -catenin
increases dramatically in the presence of a proteasome inhibitor
(ref. 20 and Fig. 2a). These observations indicate that the protea-
some machinery in these human cancer cells (specifically, BLs) is
extremely effective for the destruction of -catenin.
As with other tumor viruses, EBV up-regulates -catenin sig-
naling in different cell systems through distinct signaling pathways
(16). In epithelial cells, the EBV product LMP2A activates -cate-
nin through inhibition of the PI3Akt pathway (29, 30). The EBV
type III latency state also stabilizes and actives -catenin in B
lymphocyte lines (20). Here, we show that the EBV oncogene,
LMP1, inhibits ubiquitin-dependent proteasomal degradation of
-catenin in B cells (Fig. 2) and that at least part of the stabilized
-catenin can activate the Tcf promoter (Fig. 3). A recent study by
Everly et al. (22) indicates that stabilized -catenin in EBV-infected
B cells is preferably localized in cytoplasm and not in the nucleus.
Indeed, detection of -catenin in the nucleus indicates its possible
involvement in transcription, but the amount of the protein in the
nucleus does not necessarily reflect the level of transcriptional
activity (3). In this case, the use of a Tcf reporter can show the
differences in -catenin transcriptional activity. In type III latently
EBV-infected B cells, we detected stabilized -catenin in both
nucleus and cytoplasm (C. Mayer and J.S., unpublished data).
Observations on -catenin cytoplasmic localization raise important
questions about other possible functions of stabilized -catenin in
EBV-infected B cells. The presence of transcriptionally active
-catenin does not eliminate the ability of another pool of -catenin
to take part in cell adhesion signaling, but the role of -catenin
as part of adhesion signaling in lymphoid cells requires further
investigation.
The step of ubiquitination is critical for the normal elimination
process through UPS (24). Regulation of -catenin by phosphory-
lation-dependent elimination through UPS and the role of GSK3
in this process have been well documented (2, 5, 6). In perfect
conformity with previous studies, our results indicate that GSK3-
dependent destruction machinery is active in B lymphoma cells: As
expected, both nonphosphorylable mutant -catenin and the
GSK3 pharmacological inhibitor, LiCl, successfully stabilize and
activate -catenin (Fig. 3). At the same time, the observation that
LMP1 is able to enhance -catenin stabilization and transcriptional
activity further when GSK3 is inhibited (Fig. 3) indicates that,
besides the GSK3-dependent pathway, other destruction machin-
ery for -catenin is functional in these cells. Evidence of this
possibility for -catenin has been reported by different research
groups in distinct model systems (31–36).
Our results implicate the Siah-1 ubiquitin ligase as a part of the
-catenin ubiquitin-proteasome destruction machinery active in B
lymphoma cells. Experiments with enzymatically inert mutant
indicate that ubiquitinating activity of Siah-1 is required for reduc-
tion of -catenin protein levels (Fig. 4c) and transcriptional activity
(Fig. 4b). Furthermore, the inhibition of Siah-1 expression by
siRNA has a stabilizing effect on -catenin levels (Fig. 4d). Our
results, along with recent studies of inactivating mutations of the
Siah-1 gene in gastric cancer (32), support the role of the endog-
enous Siah-1 pathway in -catenin destruction.
Our data demonstrate that the EBV oncogene LMP1 up-
regulates -catenin in B-cells, and we suggest that LMP1 stabi-
lizes -catenin by inhibiting the Siah-1 ligase. Our results show
that expression of LMP1 reduces Siah-1 RNA levels (Fig. 5),
which indicates that LMP1 might reduce transcription of Siah1
gene. The expression of Siah-1 has been attributed to regulation
by p53 (8, 9); aberrant accumulation of -catenin in tumors is
associated with inactivation of the p53 gene in hepatocellular
Fig. 5. LMP1 inhibits Siah-1 expression on the transcriptional level. Total RNA purified from LMP1-transfected DG75 cells was subjected to RT-PCR (Left). The
level of Siah-1 transcripts was quantified by real-time RT-PCR (Right). Siah-1 expression in each LMP1-transfected sample is shown in term of relative qualification
compared with expression of GAPDH, which has been ascribed an arbitrary value of 1. (Error bars  SD, n  2 in each group.)








carcinoma (37). Stabilization of -catenin is not a hallmark of
BLs (20, 22). On the other hand, differences observed in
-catenin levels in B lymphoma cell lines (15, 22) might be
explained, for example, by variations in p53 transcriptional
activity due to p53 mutations that are frequently detected in BLs
(13). There is also a possibility that LMP1 might affect the
expression level of Siah-1 through the inhibition of activity of
other transcriptional factors. The promoter region of Siah-1 was
recently identified (38), but its regulation is still unexplored.
Finally, Siah-1 itself is a target for ubiquitination and proteasomal
degradation (10), so it is possible that LMP1 may regulate Siah1 not
only at the RNA level, but at the level of protein stability as well.
In type III EBV latency, -catenin is stabilized through regulation
of the ubiquitin system, specifically through deubiquitination (20).
Possibly both ubiquitination and deubiquitination then might be
involved in -catenin regulation not only directly, but also indirectly,
in upstream steps.
In general, the existence of more than one pathway for ubiquitin-
dependent degradation of -catenin in the same cells may seem
redundant but simultaneously provides an important step in un-
derstanding how cells can regulate -catenin levels. It is tempting
to speculate that different ubiquitin-proteasome machineries might
be, for example, cell compartment-specific. In any event, destruc-
tion of -catenin in BLs sets an example through which the
regulation of the same target protein lifetime by UPS can be
effectively controlled by distinct molecular mechanisms. The im-
plication of Siah-1 in -catenin proteasomal degradation in B
lymphoma cells raises many important questions about the regu-
lation of Siah-1-dependent ubiquitin ligase complex in these cells in
general and by an oncogenic virus specifically. It should be noted
that besides -catenin, there are other known targets for Siah-1-
dependent ubiquitination (11, 12). Therefore, the ultimate biolog-
ical significance of our observation that an EBV oncogene regulates
the Siah-1 ubiquitin ligase remains to be established.
This study demonstrates the coexistence of two ubiquitin-
proteasome systems of -catenin degradation (namely, GSK3-
dependent and Siah-1-dependent) in the same human cancer cells,
and it shows that the product of a tumor virus can dysregulate the
latter system on the level of ubiquitin ligase, thus pointing to a
biological significance for the endogenous Siah-1-dependent mech-
anism (Fig. 6). Participation of LMP1 in -catenin regulation,
however, does not necessarily mean that LMP1 is the major
determinant of -catenin levels in EBV-transformed B cells. From
the virus perspective, it is likely that different EBV products in type
III latency can synergistically cooperate in stabilization and activa-
tion of -catenin and operate through distinct signaling pathways
(15, 17).
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Fig. 6. Working model of ubiquitin-dependent proteasome pathways for
-catenin in B lymphoma cells. Ubiquitinproteasome machinery for -catenin
destruction is highly effective in BL cells. At least two ubiquitin-dependent
proteasome pathways for -catenin degradation are active in these cells. One
pathway is the classical degradation of -catenin through the SCF-TrCP ubiq-
uitin ligase complex that depends on phosphorylation of -catenin by GSK3
kinase. Another pathway is through ubiquitination of -catenin by the Siah-
1SIP-Skp1-Ebi complex. The EBV oncogene LMP1 can up-regulate -catenin in B
lymphoma cells by inhibition of the latter: Siah-1-dependent ubiquitination.
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